Genentech, Idec develop anti-CD20 antibodies; Ocrevus, mosunetuzumab part of collaboration, glofitamab added
Genentech and Idec Pharmaceuticals (develops, sells immunotherapies) agreed to co-develop and sell humanized anti-CD20 molecules effective against a variety of B-cell disorders, including autoimmune diseases and cancer.
- Large Molecule
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.